Filip Janku

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Targeted therapy in non-small-cell lung cancer--is it becoming a reality?
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 7:401-14. 2010
  2. ncbi request reprint Novel therapeutic targets in non-small cell lung cancer
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:1601-12. 2011
  3. ncbi request reprint Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA Electronic address
    Cell Rep 6:377-87. 2014
  4. ncbi request reprint Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
    Prasanth Ganesan
    Corresponding Author Filip Janku, Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8 2018, Box 0455, Houston, Texas 77030
    Mol Cancer Ther 12:2857-63. 2013
  5. pmc Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 0455, Houston, TX 77030, USA
    Target Oncol 8:183-8. 2013
  6. pmc A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 4:463-73. 2013
  7. doi request reprint Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009
    Filip Janku
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6356-63. 2012
  8. pmc PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012
  9. pmc PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:276-84. 2013
  10. pmc Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 16:327-35. 2011

Collaborators

Detail Information

Publications46

  1. doi request reprint Targeted therapy in non-small-cell lung cancer--is it becoming a reality?
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 7:401-14. 2010
    ..Novel drugs aimed at these abnormalities are already in the clinic. This Review outlines the current state-of-the-art research for targeted therapy in NSCLC...
  2. ncbi request reprint Novel therapeutic targets in non-small cell lung cancer
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:1601-12. 2011
    ..This review describes molecular targets in non-small cell lung cancer that are in development or being clinically applied and their implications for developing novel anticancer therapies for this previously refractory malignancy...
  3. ncbi request reprint Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA Electronic address
    Cell Rep 6:377-87. 2014
    ..This work provides further important clinical validation for continued and accelerated use of biomarker-driven trials incorporating rational drug combinations...
  4. ncbi request reprint Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
    Prasanth Ganesan
    Corresponding Author Filip Janku, Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8 2018, Box 0455, Houston, Texas 77030
    Mol Cancer Ther 12:2857-63. 2013
    ..PIK3CA mutations are associated with simultaneous KRAS mutations, possibly accounting for therapeutic resistance...
  5. pmc Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 0455, Houston, TX 77030, USA
    Target Oncol 8:183-8. 2013
    ..These results suggest that NRAS mutation merits further investigation as a potential biomarker predicting the efficacy of bevacizumab-based treatment...
  6. pmc A kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 4:463-73. 2013
    ..Collectively, these experiments suggest that IGF-1R, has kinase-independent biologic functions and provide a rationale for combining anti-IGF-1R antibodies or siRNA and IGF-1R small molecule inhibitors...
  7. doi request reprint Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009
    Filip Janku
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6356-63. 2012
    ..We analyzed the outcomes of single-agent phase II clinical trials in non-small cell lung cancer (NSCLC) to determine trial parameters that predicted clinical activity...
  8. pmc PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012
    ..PIK3CA mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/AKT/mTOR pathway inhibitors...
  9. pmc PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 73:276-84. 2013
    ..6, 95% confidence interval (CI), 1.02-43.0, P = 0.047). Our data suggest that interaction between PIK3CA mutation H1047R versus other aberrations and response to PI3K/AKT/mTOR axis inhibitors warrants further exploration...
  10. pmc Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 16:327-35. 2011
    ..The outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated in phase I clinical trials have not been systematically analyzed...
  11. doi request reprint Unusual presentation of gastrointestinal stromal tumor with early cerebral involvement
    Filip Janku
    Department of Oncology, Bon Secours Hospital, Cork, Republic of Ireland
    Ir J Med Sci 180:765-6. 2011
    ..Metastatic spread to the brain is anecdotal. This is a case study describing metastatic GIST with early cerebral involvement and resistance to therapy with KIT tyrosine kinase inhibitor imatinib mesylate...
  12. doi request reprint Autophagy as a target for anticancer therapy
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 8:528-39. 2011
    ..To improve our understanding of autophagy in human cancers new methods for measuring autophagy in clinical samples need to be developed. This Review delineates the possible role of autophagy as a novel target for anticancer therapy...
  13. pmc Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Texas, USA
    Oncotarget 4:772-84. 2013
    ..We therefore investigated the outcome of EGFR inhibitor-based combination regimens in patients with heavily-pretreated non-small cell lung cancer (NSCLC) referred to a Phase I Clinic...
  14. pmc PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22769. 2011
    ..Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis...
  15. ncbi request reprint Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer
    Prasanth Ganesan
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 31:1505-13. 2013
    ..Lenalidomide, an immunomodulatory and anti-angiogenic drug, and temsirolimus, an mTOR inhibitor, have synergistic anti-cancer effects in preclinical models. We conducted a phase I study of the combination in patients with advanced cancers...
  16. pmc KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e38033. 2012
    ..To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents...
  17. doi request reprint Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 18:6373-83. 2012
    ..We initiated a personalized medicine program in the context of early clinical trials, using targeted agents matched with tumor molecular aberrations. Herein, we report our observations...
  18. pmc PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, FC8 2057, Box 0455, Houston, TX 77030, USA
    Mol Cancer Ther 10:558-65. 2011
    ..5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations...
  19. ncbi request reprint MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study
    David S Hong
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, MD Anderson Cancer Center, Houston TX, USA Electronic address
    Lancet Oncol 15:656-66. 2014
    ..We aimed to assess the safety and tolerability of MABp1 for interleukin-1α blockade in a refractory cancer population...
  20. pmc PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    Filip Janku
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:777-82. 2012
    ..Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance...
  21. doi request reprint Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1422-8. 2012
    ....
  22. ncbi request reprint Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 73:495-501. 2014
    ..We conducted a phase I study of the combination of the anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers...
  23. ncbi request reprint Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:3029-38. 2014
    ..Since PI3K/AKT/mTOR pathway activation diminishes the effects of hormone therapy, combining aromatase inhibitors (anatrozole) with mTOR inhibitors (everolimus) was investigated...
  24. ncbi request reprint Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies
    Siqing Fu
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 32:465-72. 2014
    ..Preclinical data showed that trientine, a copper-lowering agent, re-sensitized cancer cells to carboplatin through enhanced human copper transporter 1 (hCtr1) -mediated platinum uptake...
  25. pmc Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses
    Jennifer Wheler
    Department of Investigational Cancer Therapeutics A Phase I Clinical Trials Program, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:890-8. 2013
    ..Thymomas and thymic carcinoma are rare tumors with no approved therapies. Our purpose was to analyze the molecular features and outcomes of patients referred to the Clinical Center for Targeted Therapy (Phase I Clinic)...
  26. doi request reprint Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer
    Prasanth Ganesan
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Invest New Drugs 32:279-86. 2014
    ..We conducted a Phase I study of lenalidomide and sorafenib in patients with advanced cancer...
  27. pmc P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy
    Rabin Said
    Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:705-14. 2013
    ..Mutations in the p53 gene are amongst the most frequent aberrations seen in human cancer. Our objective was to characterize the clinical characteristics associated with p53 mutation in patients with advanced cancer...
  28. pmc Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials
    Ishwaria M Subbiah
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:153-62. 2013
    ..Patients with advanced cholangiocarcinoma (CC) and gallbladder carcinoma (GC) have few therapeutic options for relapsed disease...
  29. ncbi request reprint Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program
    Ming Mo Hou
    Department of Investigational Cancer Therapeutics, Unit 0455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, U S A
    Anticancer Res 34:2349-55. 2014
    ..We evaluated clinical outcomes of patients with metastatic cervical cancer referred to a Phase I Clinical Trials Program...
  30. ncbi request reprint Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer
    Apostolia M Tsimberidou
    From the aDepartment of Investigational Cancer Therapeutics, and bDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Natl Compr Canc Netw 12:194-203. 2014
    ..This regimen of bendamustine (100 mg/m(2)) and bevacizumab (10 mg/kg) was well tolerated and yielded disease stabilization in selected heavily pretreated patients with advanced cancer. ..
  31. pmc FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors
    Denis L Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e89388. 2014
    ..Preclinical data suggest that FBXW7 mutations sensitize cells to mTOR inhibitors. Clinicopathologic characteristics of cancer patients with FBXW7 mutations and their responses to mTOR inhibitors remain unknown...
  32. ncbi request reprint Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, University of Texas M D Anderson Cancer Center, 1515Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:4031-7. 2010
    ....
  33. pmc A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies
    John W Moroney
    Department of Gynecology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:6840-6. 2011
    ..We, therefore, added temsirolimus (T), which inhibits HIF-1α, to D and A (DAT). Trial objectives were assessment of safety, preliminary efficacy, and identification of biological response correlates...
  34. ncbi request reprint Characteristics and survival of patients with advanced cancer and p53 mutations
    Rabih Said
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Internal Medicine, Oncology Division, The University of Texas Health Sciences Center, Houston, TX
    Oncotarget 5:3871-9. 2014
    ..15). In conclusion, our results demonstrated resistance to matched-targeted therapy to the other aberrations in patients with p53 mutations and emphasize the need to overcome this resistance. ..
  35. pmc MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
    Denis L Fontes Jardim
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, USA
    Oncotarget 5:1837-45. 2014
    ..In conclusion, MET abnormalities can be found in a small group of patients with GE adenocarcinoma and further studies are necessary to better characterize the prognostic and predictive impact of MET alterations. ..
  36. pmc Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit
    Siqing Fu
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncologist 18:1315-20. 2013
    ..We conducted this retrospective study to identify reasons that patients referred to a phase I clinical trial failed to enroll or delayed enrollment onto the trial...
  37. pmc Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms
    Jennifer J Wheler
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:2349-54. 2014
    ..The 'molecular individuality' of these tumors suggests that a customized strategy, using an "N-of-One" model of precision medicine, may represent an optimal approach for the treatment of patients with advanced tumors. ..
  38. pmc Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma
    Ahmed O Kaseb
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex, USA
    Oncology 85:197-203. 2013
    ..Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare variant of HCC. We report an analysis of the clinicopathologic features, treatment outcomes, and prognostic indicators of 94 cases...
  39. pmc Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications
    Yunyun Jiang
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 4:884-9. 2013
    ..Our pilot data suggest that PTPRD germline mutations may play a role in the development of Ewing sarcoma, a disease of young people, and their presence may have implications for therapy. ..
  40. pmc BRAF mutations in advanced cancers: clinical characteristics and outcomes
    Hazem El-Osta
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e25806. 2011
    ..We examined the clinical characteristics and outcomes of patients with mutant (mut) BRAF advanced cancer referred to phase 1 clinic...
  41. ncbi request reprint Molecular characterization of gallbladder cancer using somatic mutation profiling
    Milind Javle
    The University of Texas M D Anderson Cancer Center, Houston, TX, 77054, USA Electronic address
    Hum Pathol 45:701-8. 2014
    ..In conclusion, somatic mutation profiling using archival FFPE samples from gallbladder cancer is feasible. NGS, in particular, may be a useful platform for identifying novel mutations for targeted therapy. ..
  42. pmc A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma
    Vivek Subbiah
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
    Oncotarget 5:95-102. 2014
    ..We also expand on the role of rapamycin analogs in oncology. This study supports a role for an immune-type pathogenesis that is amenable to immune modulating targeted therapy in refractory HL...
  43. ncbi request reprint BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
    Oncotarget 5:3607-10. 2014
    ..67). Testing for BRAF V600E mutation in plasma and urine cfDNA should be further investigated as an alternative to archival tissue mutation analysis. ..
  44. pmc STAT3 inhibitors: finding a home in lymphoma and leukemia
    Javier Munoz
    Hematology Oncology, Banner, MD Anderson Cancer Center, Gilbert, Arizona, USA Hematology Oncology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA Departments of Investigational Cancer Therapeutics Phase I Clinical Trials Program and Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncologist 19:536-44. 2014
    ..Targeting the STAT pathway, which seems to be critical in tumorigenesis, is promising for multiple malignancies including lymphoma and leukemia. In this paper, we review mechanisms of action, failures, and successes of STAT3 inhibitors. ..
  45. pmc Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra)
    Hazem El-Osta
    Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 9:1485-8. 2010
    ..Our observation suggests that Anakinra may be an attractive therapeutic approach for refractory multicentric CD...